Abbott Laboratories (ABT) Target Raised to $143 with 35% Upside

Abbott Laboratories (ABT) trades at $105.70 with a P/E ratio of 19x forward earnings. Barclays analyst Matt Miksic has set a target price of $143, indicating a potential upside of 35%. Following the acquisition of Exact Sciences for $21 billion, Abbott raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60. Despite year-to-date declines of 16% and a revenue of $12.59 billion, analysts expect accelerating sales and earnings growth in H2 2026, positioning the company as a potential recovery play for investors.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.